A Phase 2 Study of Vigil Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

A Phase 2 Study of Vigil Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Gradalis
  • Most Recent Events

    • 04 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 May 2017.
    • 04 May 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 06 Jun 2016 Planned End Date changed from 1 Feb 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top